可視光照射によるN-エチル第三級アミン類のβ,β-チオおよびセレノスルホニル化
Pallaba Ganjan Dalai1, Dinabandhu Barik1, Supriya Manna1
1Department of Chemistry, Indian Institute of Technology Guwahati, 781039, Assam, India. patel@iitg.ac.in.
まとめ
本研究では、金属や酸化剤を使用せずに、N-エチル第三級アミンのC-Hビス官能基化のための新しい可視光法を導入し、β,β-チオおよびセレノスルホニル化エナミンを効率的に合成する。
科学分野:
- 有機化学
- 光触媒
- 合成方法論
背景:
- 第三級アミンは、医薬品および材料における重要な構成要素である。
- 効率的なC-H官能基化法は、合成の合理化に不可欠である。
- 既存の方法では、過酷な条件や金属触媒が必要な場合が多い。
研究 の 目的:
- geminal C(sp3)-Hビス官能基化のための金属および酸化剤フリーの可視光駆動戦略を開発する。
- N-エチル第三級アミンからβ,β-チオおよびセレノスルホニル化エナミンを合成する。
- エオシンYおよび電子ドナーアクセプター錯体形成を含む反応メカニズムを解明する。
主な方法:
- エオシンYを増感剤とする可視光光触媒。
- 有機チオ/セレノスルホナートからのラジカルフラグメントの生成。
- 照射下でのN-エチル第三級アミンとチオ/セレノスルホナートとの反応。
- 電子ドナーアクセプター(EDA)錯体形成の調査。
主要な成果:
- N-エチル第三級アミンのgeminal C(sp3)-Hビス官能基化に成功。
- β,β-チオおよびセレノスルホニル化エナミンを良好な収率で合成。
- 金属および外部酸化剤フリーのプロトコルの実証。
- アミン活性化およびEDA錯体形成を含むメカニズムを提案。
結論:
- アミンビス官能基化のための新規かつ効率的な可視光駆動プロトコルを確立した。
- この方法は、価値のあるエナミン誘導体の合成に持続可能で実用的なアプローチを提供する。
- この発見は、光触媒ラジカル生成および官能基化戦略に関する新たな洞察を提供する。
関連する概念動画
Nomenclature of Secondary and Tertiary Amines
5.2K
The secondary and tertiary amines are derivatives of ammonia, where two and three of its hydrogens are replaced by alkyl groups, respectively. Secondary and tertiary amines can be symmetrical with identical alkyl groups attached to the nitrogen atom or unsymmetrical when more than one type of alkyl group is present. The standard nomenclature of secondary and tertiary amines is similar to the names given to the primary amines. They are generally named alkylamines. As depicted in Figure 1, for...
5.2K
TGF - β Signaling Pathway
10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
Adrenergic Receptors: β Subtype
3.8K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Antianginal Drugs: Nitrates and β-Blockers
1.6K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.6K
Antihypertensive Drugs: Types of β-Blockers
1.7K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.7K
Heart Failure Drugs: β-Blockers
920
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
920


